Lupin appoints 2 new independent directors
Lupin has appointed Jeffrey Kindler and Alfonso “Chito” Zulueta as independent directors to its board.
Kindler is an experienced healthcare executive, investor and advisor. He brings over four decades of business experience and has held leadership positions at some of the world’s most recognized companies including Pfizer, where he served as chairman and CEO, as well as McDonald’s and General Electric. Before that, he was a partner at law firm Williams & Connolly.
Kindler is currently CEO of Centrexion Therapeutics, a privately held biotechnology company, senior advisor to Blackstone, operating partner at ARTIS Ventures and Global Chair of GLG Institute. In addition, Kindler is a member of the board of directors of a number of companies, including Precigen, Perrigo Pharmaceuticals and Terns Pharmaceuticals. Kindler holds a Bachelor of Arts degree from Tufts University, and a Juris Doctor degree from Harvard Law School.
[Read more: Lupin receives FDA nod for 3 generics]
Zulueta spent over three decades in various roles of increasing responsibility with Eli Lilly and Company, including as vice president of global marketing, president of global oncology and critical care products and most recently, as president of international responsible for all geographies outside the United States and Canada. He also served as a corporate officer and member of Eli Lilly and Company’s executive committee. Mr. Zulueta previously served as member of the board of the European Federation of Pharmaceutical Industries and Associations and the U.S.-Japan Business Council.
Zulueta currently serves as non-executive chairman of the board of directors of Interpharma Investments, the holding company of Zuellig Pharma, one of the largest healthcare services groups in Asia. He also is president/CEO of CZ Ventures, a company focused on start-up investments, and member of the board of directors at Glooko, CTS and Bridge PayDay Solutions.
Zulueta holds an Economics undergraduate degree from De La Salle University, Manila, where he was conferred the 2023 Outstanding Alumnus Award, and an MBA degree in Marketing/Finance from the University of Virginia, Darden School of Business.
[Read more: Lupin receives FDA OK for generic Banzel]
Vinita Gupta, CEO of Lupin said, “We are delighted to welcome Jeff and Chito to our board. Their extensive experience in building healthcare institutions, strategic perspectives of our industry and deep understanding of the evolving global pharmaceutical landscape, will enable us to advance our growth plans in the years to come.”